1. Alexey S. Ball
lexball@ymail.com
cell 206/354-8625
As a research scientist, I'm excited to be part of the continually evolving oncology, biomarker and immunotherapy
fields. I have a proven track record of cutting edge research with increasing levels of responsibility and project
complexity. My experience over the last 15 years ranges from basic target exploration to biomarker discovery
involving immunotherapies in translational science.
Summary:
• 15 years of experience in oncology: from basic target exploration to biomarker discovery for use in the clinic.
• Exploration and development of oncology targets in solid tumor and hematologic cancers.
• Development and implementation of pharmacodynamic and patient stratification biomarker assays.
• Functional assays using ex vivo cells derived from tumor disaggregates, bone marrow and peripheral blood.
• Solid experience in experimental design for cell proliferation, signaling, apoptosis and pathway studies.
• Excellent troubleshooting and problem solving skills in assay and protocol development.
• Proficient in many computer applications that are relevant to research and development.
• Capable of working with a high level of independence and creativity.
• Excellent teamwork and communication skills.
• Experience in engaging with external collaborators and presenting data to a variety of audiences.
Professional history:
• January 2015 to present at Ben Tech. Flow Cytometry Consultant.
Developed flow assays (9-color panels) and trained staff in flow cytometry on an LSR-II.
• August 2008 to October 2014 at Amgen Inc. Sr Associate Scientist in Medical / Translational Sciences.
2012 to October 2014: Developed functional assays for an immunotherapy target, employing tumor disaggregations
and cell isolations for ex vivo assays and multiparametric flow cytometry (up to 10 colors). These functional assays
were elegant proof of concept studies testing the therapeutic antibody on primary tumors in culture for effects on the
tumor immune cell infiltrates (proliferation, immunophenotyping and target expression). Designed complex
antibody panels for biomarker studies on patient blood for use in an upcoming immunotherapy clinical trial. Recent
work on this target also included an intensive effort to disaggregate tumors and characterize the tumor infiltrating
lymphocytes on 50+ tumors for target expression and co-expression of important immune checkpoints.
2010 to 2012: Developed an assay for biochemical coverage of a small molecule inhibitor (a dual cell-cycle and
signaling inhibitor targeting FLT3-R and CDK4) to be implemented for a pre-clinical portal for the treatment of
Acute Myeloid Leukemia. Determined the assay feasibility of phospho-target and cell cycle for PD marker detection
and for identification of circulating AML cells in peripheral blood. Using in-house and commercially available
inhibitors, conducted proof of concept studies to validate the biomarker assay using primary ex vivo patient PBMCs
and BMMCs. This work lead to a rigorous assay qualification effort and development of a lyophilized antibody mix
(capturing immunophenotyping, pathway and cell cycle inhibition) for use in clinical trials.
Supported a cross-functional effort for an antibody-drug conjugate (ADC) program, an anti-CD70 conjugated to
DM1 (tubulin inhibitor) in Chronic Lymphocytic Leukemia. The work I did included evaluating target expression
and a downstream biomarker of the target using primary ex vivo patient cells. Cell cycle analyses and blockade of
mitosis were studied in short term (3-4 day) cultures with the primary CLL samples exposed to the ADC.
January 2009 to 2010: Took over a clinical biomarker assay to process incoming clinical samples for tumor cell
identification and apoptosis evaluation in Mantle Cell Lymphoma patients treated with TRAIL-R2 antibody.
Conducted proof of concept studies for potential combination therapies. Other responsibilities were to further
develop the clinical apoptosis assay by implementing positive controls, exploring alternate timing of post-dose
sample draws, and investigate the relationship between receptor occupancy and TR-2 expression levels.
August 2008 to December 2008: Worked as a contract temp on a cross-functional project investigating a newly
discovered ligand and a therapeutic antibody that targets its receptor. This work involved human and mouse cell
bioassays to test the ligands for activity and blockade by the antibody. Also supported the group with ELISAs.

2. Alexey Ball
lexball@ymail.com
• August '05 to July '08 at Rosetta (Merck and Co). Research Biologist in Biology Group.
Made a significant contribution to optimization of a lentiviral transduction and drug selection protocol for generating
inducible, high-level shRNA expressing cell lines. This method was adopted by the lab as the gold standard for
making inducible lines used in target validation / pathway studies. I provided guidance on the method and a service
to the lab by generating the inducible lines for ongoing oncology studies. This role in the lab was in addition to
conducting my own projects. One of which was to produce overexpression constructs of several isoforms of a cancer
target protein of interest. This project employed cloning, sequencing, overexpressing the proteins and analyzing the
success / level of expression by luciferase reporter and western blot assays. I was also involved in investigating the
effects of silencing a promising target in the APC with siRNA, inducible shRNA, flow cytometry, westerns,
Taqman, cell proliferation, apoptosis and colony formation assays. The technology I developed was highly valued
and presented throughout the company for future use. Much of my final work done at Rosetta involved exploring the
cell cycle effects of miR-106b and it’s connection to p21 (see publication below). Within this project, I spearheaded
the development of a dual luciferase assay for validating miRNA knock down of target 3’UTR expression. In
addition, I gained experience in automation and mRNA expression profiling.
• January '01 to August '05 at Cell Therapeutics Inc. Scientist-II in Cell Biology Group.
As part of a multifunctional team, I participated in the validation of a novel oncology target candidate, LPAATβ.
Using compounds selected from library screens and medicinal chemistry, we explored drug candidates effects on
cell signaling pathways, apoptosis and proliferation (see publication below). Techniques that I employed included
RNAi, western blot, PCR, bDNA, flow cytometry and fluorescence microscopy. As a junior scientist, I displayed
exceptional public speaking skills and was selected to present results at meetings with external collaborators, senior
management and a scientific advisory board. I was also a major contributor to a research effort to expand a currently
marketed drug to additional oncology indications. This involved exploring drug combinations in a variety of tumor
cell types and testing the potential to synergize in cytotoxicity and proliferation assays. My role in the group project
was to conduct these efforts in metastatic melanoma cell lines. I first characterized constitutive signaling pathways
in these lines, then using this data and our knowledge of our drug’s MOA, I produced an hypothesis for an
efficacious combination rationale and made a significant discovery by combining our drug of interest with MAP-K
pathway inhibitors. Also, as part of this effort I was one of two key personnel at the company to evaluate,
recommend and then utilize a new high content imaging technology and used this to help test the drug combination
hypothesis.
• May '99 to January '01 at Fred Hutchinson CRC. Research Tech-I in Clinical Immunogenetics Lab.
Began my work in blood processing isolating lymphocytes from patients and donors for HLA typing in bone
marrow transplants. Because patient lives depended on it, this work impressed upon me the importance of highly
organized work habits, attention to detail and maintaining accurate records. Due to my diligence and trustworthy
record keeping, I was quickly promoted to DNA typing the C-antigen by using SSP technology and updating patient
/ family records for HLA matching and family haplotyping.
• June '97 to April '99 at Evergreen State College. Research Tech in T4 Bacteriophage Lab.
I began as an intern then continued as part-time staff studying the infection of stationary phase E. coli by the T4-
bacteriophage. The work involved radiolabeling synchronized E. coli, infecting the cells with T4-phage and
investigating global shifts in protein expression after infection using 2D and 1D SDS-PAGE.

3. Alexey Ball
lexball@ymail.com
Summary of skills:
Cell Biology Experience:
• Multiparametric flow cytometry:
LSR-II (10 color) / FACS Calibur
PD assay development / Cell cycle /
Apoptosis / Immunophenotyping
• RNAi: siRNA / shRNA / miRNA
• Inducible shRNA / miRNA cell line generation
• Lentiviral delivery for stable expressing lines
• Cell proliferation / cytotoxicity assays
• Fluorescence microscopy
• Chemotaxis and colony formation assays
• Cell fractionation
Molecular Biology Experience:
Protein Assays
• 2D and 1D gel electrophoresis
• Westerns / ELISAs / Immunoprecipitations
• ARIA (Activated Ras Interaction Assay)
• Protein translocation assays
Biomarker Experience:
• Pharmacodynamic and patient stratification
• Proof of concept studies
• Implementing assays for the clinic
• Characterizing patient circulating tumor cells
• Large and small molecule drugs in clinic
• Hematologic and solid tumor malignancies
DNA/RNA Assays
• Isolation & purification: RLT / Trizol
• Taqman / RT-PCR / bDNA
• PCR / Sequencing / Cloning
• Luciferase reporter assays
Computer Experience:
• Windows / Excel / PowerPoint / Word
• Photoshop / Flowjo / CalcuSyn
• PubMed / BLAST / Cell Quest
• Graph Pad Prism / Spotfire
Mammalian Tissue / Cell Culture:
• Tissue disaggregation
• Cell isolation using Miltenyi systems
• Tumor lines: suspension and adherent
• Primary cells in culture
VSMCs and HMVECs
Ex vivo PBMCs and BMMCs from a variety
of hematologic malignacies
Ex vivo tumor disaggregates
• Automation
• Maintenance / Expanding / Cryopreservation
• High content imaging analysis (Amnis)
Experimental Design:
• Literature searches for protocol development
• Optimizing parameters: single or matrix
• Trouble shooting difficult parameters
• siRNA and PCR Primer design
• Automation for desired throughput
Drug Development Experience:
• Target Validation
• Compound MOA investigations
• Drug titration / time-course studies
• Drug combination & synergy analyses
• Team experience involving multiple disciplines
Professional Experience:
• Engaging with external collaborators
• Presenting data to large and small audiences
• Communicating effectively to senior management
• Attending conferences / poster presentation
• Co-author of journal articles
• Training & supervision of interns
• Technology implementation

4. Alexey Ball
lexball@ymail.com
Publications:
Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson
AL, Linsley PS, Cleary MA. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle
progression. Molecular Cell Biology, 2008 Apr;28(7):2167-74.
Michael Coon, Alexey Ball, Jeannine Pound, Sophe Ap, David Hollenback, Thayer White, John Tulinsky, Lynn
Bonham, Deborah K Morrison, Robert Finney, and Jack W Singer. Inhibition of lysophosphatidic acid
acyltransferase-b disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells.
Molecular Cancer Therapeutics, 2003 Oct;2(10): 1067-78.
David W Leung, Chris Tompkins, Jim Brewer, Alexey Ball, Mike Coon, Valerie Morris, David Waggoner and Jack
W Singer. Phospholipase Cd-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and
proliferation in MCF-7 cells. Molecular Cancer, 2004 3:15.
Selected abstracts:
de Vries, P., Bonham, L., Martin, T., Stone, I., Anderson, M., Moses, J., Pound J., Ball, A., Hollenback, D., Coon,
M., and Singer, J. W. CT-32228: A lysophosphatidic acid acyltransferase-beta (LPAAT-β) inhibitor, induces
apoptosis in a variety of solid tumor, leukemia and lymphoma cell lines, but not in normal cells. Eur.J Cancer 38
(Suppl 7), S96. 2002. Frankfurt, Germany.
Coon, M. E., Ball, A., Pound, J., Ap, S., de Vries, P., Tulinsky, J., and Singer, J. W. RNAi Knockdown of
Lysophosphatidic Acid Acyltransferase-β (LPAAT-β) Activity Disrupts RAS-RAF-ERK and PI3K/AKT/mTOR
Pathways and Selectively Induces Tumor Cell Apoptosis. Proceedings of the American Society of Hematology
2002, 715. 2003. Philadelphia, PA (paper selected for presentation at symposia).
Coon, M. E., Ball, A., Bonham, L., de Vries, P., Pound, J., Ap, S., and Singer, J. Inhibition of lysophosphatidic acid
acyltransferase-β (LPAAT-β) by CT-32228 inhibits activation of RAS-RAF-Erk and PI3K/AKT/m-TOR. 1st
International Symposium on Signal Transduction Modulators in Cancer Therapy Proceedings , 83. 2002.
Amsterdam, The Netherlands (paper selected for plenary speech).
Coon, M. E., Ball, A., Bonham, L., Pound, J., Ap, S., de Vries, P., and Singer, J. W. Inhibition of lysophosphatidic
acid acyltransferase-beta (LPAAT-β) by CT-32228 inhibits activation of RAS-RAF-Erk and PI3K/AKT/m-TOR
pathways and selectively induces tumor cell apoptosis. Proceedings of the 2003 AACR, 2771. 2003. Washington
D.C. USA
Education:
Bachelor of Science in Cell Biology & Bachelor of Arts in Music. Evergreen State College in Olympia, WA (1998)
References:
Katie Newhall, Ph.D.: Most recent supervisor and formerly a Principle Scientist in Medical Sciences at Amgen Inc.:
katienewhall@comcast.net
Yang Pan, Ph.D.: Former Director of Medical Sciences at Amgen Inc.: Klucherpan@gmail.com
Gary Means, Ph.D.: Currently a Principle Scientist in Medical Sciences at Amgen Inc.: meansg@amgen.com
Lynn Bonham, Ph.D.: Former supervisor at both Amgen and Cell Therapeutics, Inc. Currently an associate Director at
Seattle Cancer Care Alliance: lbonham7@comcast.net